Guided Biopsy for Mapping Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/1/2014
Start Date:May 2010
End Date:May 2016
Contact:Roswell Park Cancer Institute
Email:AskRPCI@roswellpark.org
Phone:1-877-275-7724

Use our guide to learn which trials are right for you!

Hybrid Imaging Technique (HIT) Guided Biopsy to Map Prostatic Adenocarcinoma in Patients Undergoing Prostatectomy

Evaluate the accuracy of HIT guided biopsies for mapping tumor foci with men undergoing
prostatectomy.

The objective of this study is to determine the accuracy of HIT (Hybrid Imaging Technology)
guided biopsies for mapping tumor foci with men undergoing prostatectomy. Using a prostate
hybrid imaging technology (HIT) which fuses a previously obtained endorectal MR image to
transrectal ultrasound (TRUS) image to allow identification and biopsy of tumors by MR
imaging in real time. We hypothesis that HIT guided biopsies will accurately localize the
foci of prostate cancer.

Inclusion Criteria:

- Patients must have histologically confirmed diagnosis of prostate cancer

- Patients must have elected to undergo radical prostatectomy using an open,
laparoscopic or robotic approach

- Patients must be at least 18 years of age and able to provide written informed
consent.

- No history of radiotherapy, chemotherapy or hormone therapy within 6 months of
surgery

- Primary tumor must be amenable to surgical removal for curative intent

- Patients must have ECOG-performance status 0 or 1 (appendix II)

- Patients must have no history of rectal or anal disease.

- Patients must have adequate organ function as defined by the following criteria:

- Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase
[SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase
[SGPT])≤2.5x local laboratory upper limit of normal (ULN), or AST and ALT ≤5x
ULN if liver function abnormalities are due to underlying malignancy

- Total serum bilirubin ≤1.5 x ULN

- Absolute neutrophil count(ANC)≥1,500/microL

- Platelets≥lOO,OOO/microL

- Hemoglobin≥9.0 g/dL

- Serum calcium≤10.2mg/dL (correct for low albumin if necessary; calcium + (normal
albumin - serum albumin)x 0.8)

- Patients must have serum creatinine<2 mg/dL or serum creatinine clearance
(CrCl)>40ml/min(CrCl= Wt(kg)x(140-age)*/72xCr. level,*female x 0.85)

Inclusion of minorities:

- Members of all races and ethnic groups are eligible for this trial. Women and
children are not eligible since prostate cancer is not diagnosed in these groups.
We found this trial at
1
site
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials